// App-Quantinova.ai

189 : Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma.

Researchers

Presenter

  • Reinhard Dummer

Principal Investigators

  • Ana Mara Arance Fernndez

  • Johan Hansson

  • James M. G. Larkin

  • Georgina V. Long

  • Eduard Gasal

  • Mathilde Kaper

  • Allison Upalawanna

  • Bijoyesh Mookerjee

  • Victoria Atkinson

Medical Centers

  • University Hospital Zurich Skin Cancer Center, Zurich, Switzerland

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Karolinska Institutet, Stockholm, Sweden

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • Novartis AG, Basel, Switzerland

  • Princess Alexandra Hospital, Gallipoli Medical Research Foundation, University of Queensland, Qld, Australia

Locations

  • Switzerland

  • Spain

  • Sweden

  • United Kingdom

  • Australia

  • United States

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Programmed cell death protein 1

Drug/Treatment

  • Dabrafenib Mesylate

  • Trametinib

  • PDR001

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

  • Cohort

Phase

  • III

Study Id's

  • NCT02967692

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved